Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate whether radiosurgery, along with standard chemotherapy, immunotherapy (the treatment of cancer by modulating the immune system and immune response), or hormonal therapy, affects the quality and length of life. The standard therapy is surgery, radiation therapy, or chemotherapy alone or in any combination. A second purpose of this study is to determine if the levels of a special type of protein (called cytokines) found in the blood are related to the quality of life while on this treatment.


Clinical Trial Description

Before treatment begins, you will have a physical exam and blood tests. Physical evaluations and blood tests will be done each week while you are receiving treatment, and at follow-up visits. You will be seen for follow-up evaluations 4 weeks after treatment is completed, and every three months thereafter. You will be asked to fill out a Quality of Life questionnaire, which should take 5-10 minutes to complete. This will be done prior to treatment and at your follow-up visits. You will receive high dose radiation therapy directed at the site of metastasis. This treatment will be given once a day, 5 times a week (Monday through Friday) for one to four weeks depending on the location and size of the disease to be treated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00167414
Study type Interventional
Source University of Rochester
Contact
Status Completed
Phase N/A
Start date December 2000
Completion date November 1, 2016

See also
  Status Clinical Trial Phase
Completed NCT03427450 - Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
Terminated NCT01067989 - Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer Phase 2
Completed NCT01045304 - Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer Phase 2
Completed NCT00288249 - Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer Phase 2
Completed NCT00044525 - Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients Phase 2